Placebo for upadacitinib film-coated tablet
Sponsors
Abbvie Deutschland GmbH & Co. KG
Conditions
Atopic DermatitisModerate and Severe Atopic Dermatitis
Phase 3
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
CompletedCTIS2022-502938-30-00
Start: 2018-12-10End: 2025-07-21Target: 187Updated: 2025-03-13
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Active, not recruitingCTIS2022-502937-24-00
Start: 2019-01-02Target: 444Updated: 2025-11-07